Jun 29, 2022 8:00 am EDT Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
Jun 21, 2022 8:00 am EDT Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference
Jun 1, 2022 8:00 am EDT Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users
May 26, 2022 8:00 am EDT Achieve Life Sciences Announces Participation at LD Micro Invitational Conference
May 13, 2022 8:00 am EDT Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
May 12, 2022 4:00 pm EDT Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update
Apr 27, 2022 8:00 am EDT Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers
Apr 21, 2022 8:00 am EDT Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022
Mar 15, 2022 8:00 am EDT Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting